Genentech, Celgene and other biotech firms seeking to expand their share of the cancer drug market are preparing to present data on their experimental treatments at the American Society of Clinical Oncology's annual meeting in Chicago. Aside from Celgene's Revlimid and Genentech's Avastin, industry experts are also betting on Erbitux -- made by Merck KGaA, ImClone Systems and Bristol-Myers Squibb Co. -- to show promising trial results.

Related Summaries